Cerebrovascular accidents and ranibizumab.
Moorthy
Sonia
S
Cheung
Ning
N
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D016208:Databases, Factual; D006801:Humans; D015994:Incidence; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D009203:Myocardial Infarction / Q000139:chemically induced / Q000453:epidemiology; D016017:Odds Ratio; D000069579:Ranibizumab; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced* / Q000453:epidemiology; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab